Biomarkers identified for cytokine release syndrome risk after CAR T-cell therapy

For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with improvement of cytokine merchandise syndrome (CRS) aft chimeric antigen receptor (CAR) T-cell therapy, according to a survey published successful the November contented of The Lancet Rheumatology.